...
首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.
【24h】

A comparison of treatment outcomes by radiochemotherapy and postoperative radiotherapy in locally advanced squamous cell carcinomas of head and neck.

机译:放疗与术后放疗对头颈部局部晚期鳞状细胞癌的治疗效果比较。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To investigate the treatment outcomes by concomitant radiochemotherapy (CHEMORAD), and by surgery and postoperative radiotherapy (PORT) in patients with locally advanced head and neck cancers. METHOD: A retrospective study included all patients with Stage III and IV (except T1-2 N1) diseases between 1989 and 2002 treated with CHEMORAD (163 patients) or PORT (424 patients) at the L'Hotel-Dieu de Quebec. Chemotherapy was realized with Cisplatin (DDP) 100 mg/m(2), d1, d23, and d45 during radiotherapy or weekly DDP 40 mg/m(2) for 6 weeks in case of patients with poor general condition. Neck dissection was performed if residual disease was diagnosed on CHEMORAD. For the PORT group, 410 patients had neck dissection before adjuvant treatment. RESULTS: The 2-year loco-regional control was 82% for CHEMORAD, and 72% for PORT (P = 0.01). The 2-year disease-free survival was 72% for CHEMORAD, and 64% for PORT (P = 0.02). The results were further confirmed by a Cox proportional hazard model. CONCLUSION: The results indicated that CHEMORAD is a better approach than PORT in the management of locally advanced head and neck cancers. Further randomized study will be needed to compare radical CHEMORAD with surgery plus adjuvant CHEMORAD to determine an appropriate treatment in the management of locally advanced head and neck squamous cell carcinomas.
机译:目的:探讨伴随放疗(CHEMORAD),手术和术后放疗(PORT)治疗局部晚期头颈癌患者的治疗效果。方法:一项回顾性研究纳入了1989年至2002年间在魁北克L'Hotel-Dieu医院接受CHEMORAD(163例)或PORT(424例)治疗的所有III期和IV期(T1-2 N1除外)疾病的患者。在一般情况较差的患者中,放疗期间采用顺铂(DDP)100 mg / m(2),d1,d23和d45进行化学疗法,每周DDP 40 mg / m(2)进行6周的化学疗法。如果在CHEMORAD上诊断出残留疾病,则进行颈部解剖。对于PORT组,有410例患者在接受辅助治疗前曾进行过颈部解剖。结果:CHEMORAD的2年局部区域控制为82%,PORT的为72%(P = 0.01)。 CHEMORAD的2年无病生存率是PORT的64%(P = 0.02)。 Cox比例风险模型进一步证实了该结果。结论:结果表明,在局部晚期头颈癌的治疗中,CHEMORAD比PORT更好。需要进一步的随机研究,以比较根治性CHEMORAD与手术加辅助性CHEMORAD的关系,以确定在治疗局部晚期头颈部鳞状细胞癌中的合适治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号